{"Cystic": [0, 197], "fibrosis": [1, 12, 99, 291], "is": [2], "caused": [3], "by": [4, 305], "mutations": [5], "in": [6, 60, 89, 125, 132, 161, 276, 281, 287, 296], "the": [7, 10, 29, 44, 55, 83, 196, 272, 279, 282], "gene": [8], "encoding": [9], "cystic": [11, 98, 290], "transmembrane": [13], "conductance": [14], "regulator": [15], "(CFTR)": [16], "protein,": [17], "and": [18, 48, 64, 70, 85, 145, 175, 230, 250], "nearly": [19], "90%": [20], "of": [21, 28, 87, 93, 127, 140, 151, 164, 184, 212, 271, 278], "patients": [22, 39, 90, 142, 257, 280, 288], "have": [23], "at": [24, 136, 147, 172], "least": [25, 148], "one": [26, 149], "copy": [27], "Phe508del": [30, 45, 67], "CFTR": [31, 46, 57, 68, 299], "mutation.": [32], "In": [33], "a": [34, 49, 74, 162, 182, 191, 208, 231], "phase": [35, 75], "2": [36], "trial": [37, 80, 273], "involving": [38], "who": [40], "were": [41, 105, 262, 302], "heterozygous": [42], "for": [43, 113, 243], "mutation": [47, 51], "minimal-function": [50], "(Phe508del-minimal": [52], "function": [53, 69, 102, 294], "genotype),": [54], "next-generation": [56], "corrector": [58], "elexacaftor,": [59], "combination": [61], "with": [62, 97, 100, 204, 214, 289, 292], "tezacaftor": [63], "ivacaftor,": [65], "improved": [66], "clinical": [71], "outcomes.We": [72], "conducted": [73], "3,": [76], "randomized,": [77], "double-blind,": [78], "placebo-controlled": [79], "to": [81, 108, 158, 202, 216, 269], "confirm": [82], "efficacy": [84], "safety": [86], "elexacaftor-tezacaftor-ivacaftor": [88, 110, 283], "12": [91], "years": [92], "age": [94], "or": [95, 111, 154, 264], "older": [96], "Phe508del-minimal": [101, 293], "genotypes.": [103], "Patients": [104], "randomly": [106], "assigned": [107], "receive": [109], "placebo": [112], "24": [114, 180], "weeks.": [115], "The": [116], "primary": [117], "end": [118], "point": [119], "was": [120, 168, 188, 226, 236, 247, 285], "absolute": [121], "change": [122], "from": [123], "baseline": [124], "percentage": [126, 163], "predicted": [128, 165], "forced": [129], "expiratory": [130], "volume": [131], "1": [133], "second": [134], "(FEV1)": [135], "week": [137], "4.A": [138], "total": [139], "403": [141], "underwent": [143], "randomization": [144], "received": [146], "dose": [150], "active": [152], "treatment": [153], "placebo.": [155], "Elexacaftor-tezacaftor-ivacaftor,": [156], "relative": [157], "placebo,": [159], "resulted": [160], "FEV1": [166], "that": [167, 187, 225, 235, 261], "13.8": [169], "points": [170, 177, 228], "higher": [171, 178, 205, 209], "4": [173, 223], "weeks": [174], "14.3": [176], "through": [179], "weeks,": [181], "rate": [183], "pulmonary": [185], "exacerbations": [186], "63%": [189], "lower,": [190], "respiratory": [192, 217], "domain": [193], "score": [194], "on": [195], "Fibrosis": [198], "Questionnaire-Revised": [199], "(range,": [200], "0": [201], "100,": [203], "scores": [206], "indicating": [207], "patient-reported": [210], "quality": [211], "life": [213], "regard": [215], "symptoms;": [218], "minimum": [219], "clinically": [220], "important": [221], "difference,": [222], "points)": [224], "20.2": [227], "higher,": [229], "sweat": [232], "chloride": [233], "concentration": [234], "41.8": [237], "mmol": [238], "per": [239], "liter": [240], "lower": [241], "(P<0.001": [242], "all": [244], "comparisons).": [245], "Elexacaftor-tezacaftor-ivacaftor": [246], "generally": [248], "safe": [249], "had": [251, 258], "an": [252], "acceptable": [253], "side-effect": [254], "profile.": [255], "Most": [256], "adverse": [259], "events": [260, 267], "mild": [263], "moderate.": [265], "Adverse": [266], "leading": [268], "discontinuation": [270], "regimen": [274], "occurred": [275], "1%": [277], "group.Elexacaftor-tezacaftor-ivacaftor": [284], "efficacious": [286], "genotypes,": [295], "whom": [297], "previous": [298], "modulator": [300], "regimens": [301], "ineffective.": [303], "(Funded": [304], "Vertex": [306], "Pharmaceuticals;": [307], "VX17-445-102": [308], "ClinicalTrials.gov": [309], "number,": [310], "NCT03525444.).": [311]}